CRLX101 plus Avastin Does Not Show Improvement Compared to Standard of Care in this Setting
Company to Host Conference Call Today at 4:30 pm EDT
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ: CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced top-line results from the Companys Phase 2, randomized,... More